Fatigue, Traumatic Brain Injury
Conditions
Keywords
Traumatic Brain Injury, TBI, Fatigue, Post-TBI Fatigue, PTBIF, Depressed Mood, Excessive Daytime Sleepiness, Circadian Rhythm, Anxiety, Cognitive Dysfunction, Intervention, Treatment
Brief summary
This study aims to evaluate the efficacy of 4 weeks of daily light exposure in reducing Post-Traumatic Brain Injury (TBI) Fatigue immediately post-treatment and at a one-month follow up. The investigators hypothesize that individuals receiving 4 weeks of bright white light treatment will report significant reductions in fatigue compared to individuals receiving dim red light treatment for the same duration of time, and that these treatment effects will be maintained one month after treatment completion.
Detailed description
To determine the efficacy of bright white light exposure compared to dim red light exposure in reducing post-TBI fatigue, an 8-week, randomized parallel-group clinical trial will be performed. Outcome assessment will be blinded. Participants will complete a baseline battery (T1) including 72 hours of actigraphy. Participants will then be randomized to either the Bright White Light (BWL) or the Dim Red Light (DRL) group. After 4 weeks of daily, 30-minute light treatments, the baseline battery will be re-administered (T2) along with 3 more days of Actigraphy. A follow-up assessment involving the same measures will be administered 1 month-post cessation of light therapy (T3). Participant treatment allocations will be masked for research team members conducting outcome measures. Secondary outcome measures will be administered to explore the effects of light therapy on mood, daytime sleepiness, sleep quality, circadian rhythms, anxiety, cognition and life satisfaction.
Interventions
Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.
A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.
Sponsors
Study design
Eligibility
Inclusion criteria
* Documented TBI of any severity * At least 6 months post injury * Presence of clinically significant fatigue, operationalized as a score of 22 or more on the Multidimensional Assessment of Fatigue * Age 18 or older * English speaking
Exclusion criteria
* Neurological disease other than TBI * Pregnancy (because of pregnancy fatigue) * Medical illness causing fatigue, such as anemia, hypothyroidism, HIV, renal failure, cirrhosis or cancer treatment in the past year * Current major depressive episode or substance abuse * Diagnosed sleep disorder or high risk for sleep apnea * History of bipolar disorder or manic or hypomanic episodes * Current chronic, severe headaches * Sensitivity to bright light * History of retinal damage or disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Multidimensional Assessment of Fatigue (MAF) | baseline, 4 weeks, 8 weeks | Multidimensional Assessment of Fatigue (MAF) yields a Global Fatigue Index (GFI), assessing 5 dimensions of fatigue: distress, degree, severity, impact on ADLs and frequency of fatigue in the past week, and it yields a composite score. GFI full score from 0-50, with a higher score indicating more severe fatigue, fatigue distress, or impact on activities of daily living. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neuro-QOL Depression and Sleep | baseline, 4 weeks, 8 weeks | The Neuro-QOL Depression and Sleep measures the physical, mental, and social effects experienced by adults and children living with neurological conditions. Raw scores were converted to T-Scores; from 0-100, with a T = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating worse function. |
| Epworth Sleepiness Scale (ESS) | baseline, 4 weeks, 8 weeks | The Epworth Sleepiness Scale (ESS) will also be used, to assess daytime sleepiness; it is an 8-item measure that asks about the probability of dozing or sleeping during typical daytime activities and has been widely used in TBI research. Scores correlate well with objective measures of speed of daytime sleep onset. The test is a list of eight situations in which the participate rates tendency to become sleepy on a scale of 0, no chance of dozing, to 3, high chance of dozing for each item. Total scale from 0 to 24, with higher score indicating severe excessive daytime sleepiness. |
| CNS Vital Signs TBI Rehab Toolbox | baseline, 4 weeks, 8 weeks | The Centre for Neuro Skills Vital Signs TBI Rehab Toolbox is a brief, 25-minute computerized cognition battery; it emphasizes those cognitive functions that are the most likely to respond to alerting effects of light (vigilance, attention, speed) and has multiple forms for serial assessment. The scores are reported as Standard Scores, with mean = 100 and standard deviation = 15. Higher scores are correlated with better outcomes. |
| Cognitive Failures Questionnaire | baseline, 4 weeks, 8 weeks | The Cognitive Failures Questionnaire (CFQ)100 is a 25-item self-report inventory, with items measuring difficulties in several cognitive domains (e.g., memory, perception), each item scored from 0 (never) to 4 (very often), with total scale from 0 - 100, with higher score indicating worse outcome. |
| Neuro-QOL Anxiety | baseline, 4 weeks, 8 weeks | The Neuro-QOL Anxiety measure. Raw scores were converted to T-Scores; from 0-100, with a T = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating worse anxiety. |
| TBI-QOL Fatigue | baseline, 4 weeks, 8 weeks | The Traumatic Brain Injury-Quality Of Life Fatigue (TBI-QOL) measures form part of the Promis Neuro-QOL initiative and include well-validated self-report measures that assess the health-related QOL of individuals with neurological disorders. All TBI-QOL scores have been transformed to a T metric,from 0-100, with a mean of 50 (SD = 10), with a higher score indicating more fatigue. |
| Actiwatch Spectrum - Mesor | 4 weeks post treatment | Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. Mesor is an adjusted proportion of the difference between the minimum and half the peak, so range is 0-1. Higher means a more rhythmic pattern. |
| Actiwatch Spectrum - F Statistic | 4 weeks post treatment | Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. F statistic is an F value, so the range is 0 - infinity. It compares two different models of calculating the curve. Higher means a more rhythmic pattern. |
| Satisfaction With Life Scale | baseline, 4 weeks, 8 weeks | Satisfaction with Life Scale, a 5-item measure of global satisfaction with life, on likert scale from 1 strongly disagree to 7 strongly agree. Total scale from 5 to 35, with higher scores indicating more satisfaction with life, and 20 representing a neutral point on the scale. |
| Treatment Satisfaction Questionnaire for Medication | at 4 weeks (end-of-treatment) | An adapted version of the Treatment Satisfaction Questionnaire for Medication (TSQM). This is a validated, psychometrically sound measure of general treatment satisfaction. The TSQM scores range from 0 to 100 with higher scores representing higher satisfaction. |
| Credibility/Expectancy Questionnaire | at 4 weeks (end-of-treatment) | Assess treatment credibility (BWL vs. DRL) with the Credibility/Expectancy Questionnaire (CEQ), used in clinical outcome studies. The CEQ utilizes two scales during the administration (1-9, and 0-100%), and so a composite z score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean. A higher score indicates more belief or feeling of reduction in anxiety. |
| Actiwatch Spectrum - Acrophase | 4 weeks post treatment | Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. Acrophase is time of the peak activity, so it is expressed in hours. The higher the number, the later in the day the peak activity occurs. |
Countries
United States
Participant flow
Recruitment details
From October 2015-January 2017, recruitment materials were sent to previous research and support group participants, and other local TBI centers. Information was also posted online and at consumer conferences. External sites included Centre for Neuro Skills facilities and post-acute rehab centers in Bakersfield and Los Angeles, CA, and Dallas, TX.
Participants by arm
| Arm | Count |
|---|---|
| Bright White Light (BWL) Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box. | 44 |
| Dim Red Light (DRL) Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL. | 44 |
| Total | 88 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 |
| Overall Study | Lost to Follow-up | 1 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 9 |
Baseline characteristics
| Characteristic | Bright White Light (BWL) | Dim Red Light (DRL) | Total |
|---|---|---|---|
| Age, Continuous | 48.045 years STANDARD_DEVIATION 16.335 | 45.182 years STANDARD_DEVIATION 13.138 | 46.614 years STANDARD_DEVIATION 14.808 |
| Race/Ethnicity, Customized Asian/Pacific Islander | 2 Participants | 5 Participants | 7 Participants |
| Race/Ethnicity, Customized Black or African American | 6 Participants | 5 Participants | 11 Participants |
| Race/Ethnicity, Customized Hispanic/Latino | 5 Participants | 8 Participants | 13 Participants |
| Race/Ethnicity, Customized More than one race/Other | 4 Participants | 3 Participants | 7 Participants |
| Race/Ethnicity, Customized White | 27 Participants | 23 Participants | 50 Participants |
| Sex: Female, Male Female | 20 Participants | 24 Participants | 44 Participants |
| Sex: Female, Male Male | 24 Participants | 20 Participants | 44 Participants |
| Years of education completed | 15.841 years STANDARD_DEVIATION 2.533 | 15.651 years STANDARD_DEVIATION 2.654 | 15.747 years STANDARD_DEVIATION 2.58 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 44 | 0 / 44 |
| other Total, other adverse events | 1 / 44 | 0 / 44 |
| serious Total, serious adverse events | 0 / 44 | 0 / 44 |
Outcome results
Multidimensional Assessment of Fatigue (MAF)
Multidimensional Assessment of Fatigue (MAF) yields a Global Fatigue Index (GFI), assessing 5 dimensions of fatigue: distress, degree, severity, impact on ADLs and frequency of fatigue in the past week, and it yields a composite score. GFI full score from 0-50, with a higher score indicating more severe fatigue, fatigue distress, or impact on activities of daily living.
Time frame: baseline, 4 weeks, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bright White Light (BWL) | Multidimensional Assessment of Fatigue (MAF) | Baseline | 33.332 score on a scale | Standard Deviation 9.043 |
| Bright White Light (BWL) | Multidimensional Assessment of Fatigue (MAF) | 4 weeks (end of treatment) | 27.993 score on a scale | Standard Deviation 9.993 |
| Bright White Light (BWL) | Multidimensional Assessment of Fatigue (MAF) | 8 weeks (one month post treatment) | 28.658 score on a scale | Standard Deviation 12.213 |
| Dim Red Light (DRL) | Multidimensional Assessment of Fatigue (MAF) | Baseline | 30.531 score on a scale | Standard Deviation 10.633 |
| Dim Red Light (DRL) | Multidimensional Assessment of Fatigue (MAF) | 4 weeks (end of treatment) | 24.937 score on a scale | Standard Deviation 10.558 |
| Dim Red Light (DRL) | Multidimensional Assessment of Fatigue (MAF) | 8 weeks (one month post treatment) | 25.350 score on a scale | Standard Deviation 10.895 |
Actiwatch Spectrum - Acrophase
Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. Acrophase is time of the peak activity, so it is expressed in hours. The higher the number, the later in the day the peak activity occurs.
Time frame: 4 weeks post treatment
Population: After the Actigraph data were cleaned and analyzed, there was clean, usable data for 30 in the white arm and 23 in the red arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Bright White Light (BWL) | Actiwatch Spectrum - Acrophase | 15.68 hours | Standard Deviation 2.29 |
| Dim Red Light (DRL) | Actiwatch Spectrum - Acrophase | 15.98 hours | Standard Deviation 1.09 |
Actiwatch Spectrum - F Statistic
Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. F statistic is an F value, so the range is 0 - infinity. It compares two different models of calculating the curve. Higher means a more rhythmic pattern.
Time frame: 4 weeks post treatment
Population: After the Actigraph data were cleaned and analyzed, there was clean, usable data for 30 in the white arm and in the 23 red arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Bright White Light (BWL) | Actiwatch Spectrum - F Statistic | 1765.36 score on a scale | Standard Deviation 1120.32 |
| Dim Red Light (DRL) | Actiwatch Spectrum - F Statistic | 2307.38 score on a scale | Standard Deviation 1574.54 |
Actiwatch Spectrum - Mesor
Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep. Mesor is an adjusted proportion of the difference between the minimum and half the peak, so range is 0-1. Higher means a more rhythmic pattern.
Time frame: 4 weeks post treatment
Population: After the Actigraph data were cleaned and analyzed, there was clean, usable data for 30 in the white arm and 23 in the red arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Bright White Light (BWL) | Actiwatch Spectrum - Mesor | 0.72 score on a scale | Standard Deviation 0.21 |
| Dim Red Light (DRL) | Actiwatch Spectrum - Mesor | 0.83 score on a scale | Standard Deviation 0.25 |
CNS Vital Signs TBI Rehab Toolbox
The Centre for Neuro Skills Vital Signs TBI Rehab Toolbox is a brief, 25-minute computerized cognition battery; it emphasizes those cognitive functions that are the most likely to respond to alerting effects of light (vigilance, attention, speed) and has multiple forms for serial assessment. The scores are reported as Standard Scores, with mean = 100 and standard deviation = 15. Higher scores are correlated with better outcomes.
Time frame: baseline, 4 weeks, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bright White Light (BWL) | CNS Vital Signs TBI Rehab Toolbox | baseline | 79.59 score on a scale | Standard Deviation 26.26 |
| Bright White Light (BWL) | CNS Vital Signs TBI Rehab Toolbox | 4 weeks (end of treatment) | 83.19 score on a scale | Standard Deviation 27.489 |
| Bright White Light (BWL) | CNS Vital Signs TBI Rehab Toolbox | 8 weeks (one month post treatment) | 86.17 score on a scale | Standard Deviation 28.051 |
| Dim Red Light (DRL) | CNS Vital Signs TBI Rehab Toolbox | baseline | 82.83 score on a scale | Standard Deviation 21.805 |
| Dim Red Light (DRL) | CNS Vital Signs TBI Rehab Toolbox | 4 weeks (end of treatment) | 77.64 score on a scale | Standard Deviation 37.658 |
| Dim Red Light (DRL) | CNS Vital Signs TBI Rehab Toolbox | 8 weeks (one month post treatment) | 79.10 score on a scale | Standard Deviation 35.443 |
Cognitive Failures Questionnaire
The Cognitive Failures Questionnaire (CFQ)100 is a 25-item self-report inventory, with items measuring difficulties in several cognitive domains (e.g., memory, perception), each item scored from 0 (never) to 4 (very often), with total scale from 0 - 100, with higher score indicating worse outcome.
Time frame: baseline, 4 weeks, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bright White Light (BWL) | Cognitive Failures Questionnaire | baseline | 47.823 score on a scale | Standard Deviation 16.872 |
| Bright White Light (BWL) | Cognitive Failures Questionnaire | 4 weeks (end of treatment) | 45.261 score on a scale | Standard Deviation 17.59 |
| Bright White Light (BWL) | Cognitive Failures Questionnaire | 8 weeks (one month post treatment) | 47.503 score on a scale | Standard Deviation 18.204 |
| Dim Red Light (DRL) | Cognitive Failures Questionnaire | baseline | 42.806 score on a scale | Standard Deviation 15.175 |
| Dim Red Light (DRL) | Cognitive Failures Questionnaire | 4 weeks (end of treatment) | 46.564 score on a scale | Standard Deviation 16.646 |
| Dim Red Light (DRL) | Cognitive Failures Questionnaire | 8 weeks (one month post treatment) | 45.352 score on a scale | Standard Deviation 18.31 |
Credibility/Expectancy Questionnaire
Assess treatment credibility (BWL vs. DRL) with the Credibility/Expectancy Questionnaire (CEQ), used in clinical outcome studies. The CEQ utilizes two scales during the administration (1-9, and 0-100%), and so a composite z score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean. A higher score indicates more belief or feeling of reduction in anxiety.
Time frame: at 4 weeks (end-of-treatment)
Population: Compared to other outcome measures, fewer CEQ records were analyzed due to participant non-compliance.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Bright White Light (BWL) | Credibility/Expectancy Questionnaire | -.5539 score on a scale | Standard Deviation 2.577 |
| Dim Red Light (DRL) | Credibility/Expectancy Questionnaire | .4489 score on a scale | Standard Deviation 2.74 |
Epworth Sleepiness Scale (ESS)
The Epworth Sleepiness Scale (ESS) will also be used, to assess daytime sleepiness; it is an 8-item measure that asks about the probability of dozing or sleeping during typical daytime activities and has been widely used in TBI research. Scores correlate well with objective measures of speed of daytime sleep onset. The test is a list of eight situations in which the participate rates tendency to become sleepy on a scale of 0, no chance of dozing, to 3, high chance of dozing for each item. Total scale from 0 to 24, with higher score indicating severe excessive daytime sleepiness.
Time frame: baseline, 4 weeks, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bright White Light (BWL) | Epworth Sleepiness Scale (ESS) | baseline | 9.695 score on a scale | Standard Deviation 4.869 |
| Bright White Light (BWL) | Epworth Sleepiness Scale (ESS) | 4 weeks (end of treatment) | 8.162 score on a scale | Standard Deviation 3.927 |
| Bright White Light (BWL) | Epworth Sleepiness Scale (ESS) | 8 weeks (one month post treatment) | 8.169 score on a scale | Standard Deviation 4.041 |
| Dim Red Light (DRL) | Epworth Sleepiness Scale (ESS) | baseline | 6.970 score on a scale | Standard Deviation 4.323 |
| Dim Red Light (DRL) | Epworth Sleepiness Scale (ESS) | 4 weeks (end of treatment) | 8.312 score on a scale | Standard Deviation 3.182 |
| Dim Red Light (DRL) | Epworth Sleepiness Scale (ESS) | 8 weeks (one month post treatment) | 8.133 score on a scale | Standard Deviation 3.899 |
Neuro-QOL Anxiety
The Neuro-QOL Anxiety measure. Raw scores were converted to T-Scores; from 0-100, with a T = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating worse anxiety.
Time frame: baseline, 4 weeks, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bright White Light (BWL) | Neuro-QOL Anxiety | baseline | 55.725 T score | Standard Deviation 8.137 |
| Bright White Light (BWL) | Neuro-QOL Anxiety | 4 weeks (end of treatment) | 55.250 T score | Standard Deviation 8.929 |
| Bright White Light (BWL) | Neuro-QOL Anxiety | 8 weeks (one month post treatment) | 57.441 T score | Standard Deviation 8.073 |
| Dim Red Light (DRL) | Neuro-QOL Anxiety | baseline | 56.253 T score | Standard Deviation 7.581 |
| Dim Red Light (DRL) | Neuro-QOL Anxiety | 4 weeks (end of treatment) | 56.661 T score | Standard Deviation 7.766 |
| Dim Red Light (DRL) | Neuro-QOL Anxiety | 8 weeks (one month post treatment) | 55.226 T score | Standard Deviation 8.828 |
Neuro-QOL Depression and Sleep
The Neuro-QOL Depression and Sleep measures the physical, mental, and social effects experienced by adults and children living with neurological conditions. Raw scores were converted to T-Scores; from 0-100, with a T = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating worse function.
Time frame: baseline, 4 weeks, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bright White Light (BWL) | Neuro-QOL Depression and Sleep | Baseline | 52.893 T-score | Standard Deviation 8.033 |
| Bright White Light (BWL) | Neuro-QOL Depression and Sleep | 4 weeks (end of treatment) | 53.337 T-score | Standard Deviation 8.19 |
| Bright White Light (BWL) | Neuro-QOL Depression and Sleep | 8 weeks (one month post treatment) | 55.162 T-score | Standard Deviation 8.193 |
| Dim Red Light (DRL) | Neuro-QOL Depression and Sleep | Baseline | 82.942 T-score | Standard Deviation 7.57 |
| Dim Red Light (DRL) | Neuro-QOL Depression and Sleep | 4 weeks (end of treatment) | 52.864 T-score | Standard Deviation 7.896 |
| Dim Red Light (DRL) | Neuro-QOL Depression and Sleep | 8 weeks (one month post treatment) | 52.290 T-score | Standard Deviation 9.698 |
Satisfaction With Life Scale
Satisfaction with Life Scale, a 5-item measure of global satisfaction with life, on likert scale from 1 strongly disagree to 7 strongly agree. Total scale from 5 to 35, with higher scores indicating more satisfaction with life, and 20 representing a neutral point on the scale.
Time frame: baseline, 4 weeks, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bright White Light (BWL) | Satisfaction With Life Scale | baseline | 17.409 score on a scale | Standard Deviation 6.956 |
| Bright White Light (BWL) | Satisfaction With Life Scale | 4 weeks (end of treatment) | 17.622 score on a scale | Standard Deviation 7.154 |
| Bright White Light (BWL) | Satisfaction With Life Scale | 8 weeks (one month post treatment) | 17.441 score on a scale | Standard Deviation 6.219 |
| Dim Red Light (DRL) | Satisfaction With Life Scale | baseline | 18.698 score on a scale | Standard Deviation 7.386 |
| Dim Red Light (DRL) | Satisfaction With Life Scale | 4 weeks (end of treatment) | 18.394 score on a scale | Standard Deviation 7.925 |
| Dim Red Light (DRL) | Satisfaction With Life Scale | 8 weeks (one month post treatment) | 19.900 score on a scale | Standard Deviation 6.707 |
TBI-QOL Fatigue
The Traumatic Brain Injury-Quality Of Life Fatigue (TBI-QOL) measures form part of the Promis Neuro-QOL initiative and include well-validated self-report measures that assess the health-related QOL of individuals with neurological disorders. All TBI-QOL scores have been transformed to a T metric,from 0-100, with a mean of 50 (SD = 10), with a higher score indicating more fatigue.
Time frame: baseline, 4 weeks, 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bright White Light (BWL) | TBI-QOL Fatigue | Baseline | 61.819 T score | Standard Deviation 6.255 |
| Bright White Light (BWL) | TBI-QOL Fatigue | 4 weeks (end of treatment) | 58.071 T score | Standard Deviation 7.384 |
| Bright White Light (BWL) | TBI-QOL Fatigue | 8 weeks (one month post treatment) | 58.226 T score | Standard Deviation 8.481 |
| Dim Red Light (DRL) | TBI-QOL Fatigue | Baseline | 58.821 T score | Standard Deviation 7.533 |
| Dim Red Light (DRL) | TBI-QOL Fatigue | 4 weeks (end of treatment) | 55.724 T score | Standard Deviation 8.305 |
| Dim Red Light (DRL) | TBI-QOL Fatigue | 8 weeks (one month post treatment) | 57.252 T score | Standard Deviation 9.033 |
Treatment Satisfaction Questionnaire for Medication
An adapted version of the Treatment Satisfaction Questionnaire for Medication (TSQM). This is a validated, psychometrically sound measure of general treatment satisfaction. The TSQM scores range from 0 to 100 with higher scores representing higher satisfaction.
Time frame: at 4 weeks (end-of-treatment)
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Bright White Light (BWL) | Treatment Satisfaction Questionnaire for Medication | 42.455 score on a scale | Standard Deviation 29.827 |
| Dim Red Light (DRL) | Treatment Satisfaction Questionnaire for Medication | 47.546 score on a scale | Standard Deviation 33.112 |